Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs. Co.'s development plans focus on respiratory diseases and immuno-oncology (IO). Co.'s respiratory Anticalin-based drug candidate, PRS-060/AZD1402, antagonizes IL-4Ra, thereby inhibiting by IL-4 and IL-13, two cytokines (small proteins mediating signaling between cells within the human body) known to be primary mediators in the inflammatory cascade that cause the pathogenesis of asthma and other inflammatory diseases. Co.'s IO Anticalin-based drug candidate in its pipeline, PRS-343, is designed to target the immune receptor 4-1BB and the tumor target HER2. The PIRS stock yearly return is shown above.
The yearly return on the PIRS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PIRS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|